Participated · Seed · Nov 2025

Mirantus Health digitises and decentralises ophthalmic pre-screenings through its software platform “mira,” which equips optician shops to capture retina images, intra-ocular pressure, slit-lamp photos, refraction data and visual-acuity tests. The data are transmitted to a pool of ophthalmologists who return a written assessment within 24–48 hours, flagging any abnormalities that warrant a full medical examination. The company already serves more than 200 locations across Germany and supports scheduling through a network of over 400 partner ophthalmologists, relieving pressure on traditional practices. By 2027 Mirantus aims to scale the service to more than 1,000 sites throughout Germany, Austria and Switzerland. The solution targets growing shortages in eye-care caused by an ageing specialist workforce, with roughly 30 % of German ophthalmologists nearing retirement. Revenue metrics were not disclosed, but the firm will use fresh capital to expand geographically and enhance its software. Its value proposition centres on early detection, reduced wait times for patients and lower long-term costs for the healthcare system.

Participated · Series A · Jul 2025

Plasmacure is a Nijmegen-based MedTech company whose flagship product, PLASOMA, applies cold plasma directly to complex wounds to accelerate healing. The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma at the wound that acts as a potent antimicrobial and stimulates blood flow and cell regeneration. The company reports a randomized controlled trial in which PLASOMA closed up to 2.5 times more complex wounds than standard care. Plasmacure plans to scale globally and advance adoption of PLASOMA for indications including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. To support expansion, the company announced a €6 million Series A and secured additional financing for U.S. regulatory and reimbursement pathways. Management frames the financing as enabling a U.S. rollout and broader global commercialization.

Participated · Series A · Jul 2021

Sweetch is an Israeli company that builds an AI-driven behavior-change app which analyzes smartphone “lifeprint” data to deliver hyper-personalized, emotionally intelligent reminders. The app times messages and modulates tone to increase the likelihood users follow clinical advice, and is distributed via partnerships with healthcare organizations, pharma, payers and providers rather than as an open app. Sweetch reports "tens of thousands of users" and about 45% of patients remain active after 24 months. In a 55-person prediabetes trial run at two Johns Hopkins Clinical Research Network sites, participants who completed the three-month study increased physical activity by an average of 2.8 MET-hours, lost ~1.6 kg, and reduced A1c by ~0.1%. The company has received NIH grant support to continue testing against gold-standard interventions and plans upcoming randomized controlled trials. Sweetch says it will use the Series A proceeds to expand into the U.S. and Brazil, grow its user base, and further tailor recommendations for additional conditions. Sweetch offers a patent-pending mobile app that assesses individuals' diabetes risk with a conversion time horizon and uses algorithms to guide users to the key objectives of the Diabetes Prevention Program. The product is intended for people at risk of developing diabetes or those who may be undiagnosed. Sweetch aligns its guidance with the clinically validated diet and exercise regimen associated with the Diabetes Prevention Program. The company planned to participate in a pilot study at Johns Hopkins Medicine in the first quarter of the year. The recent financing will support Sweetch's ambition to go to market in the U.S. and to be prescribed by doctors there, leveraging the Centers for Medicare and Medicaid decision to provide reimbursement for DPP participants. Leadership includes CEO Dana Chanan, CMO and business development lead Dr. Yossi Bahagon, and CTO Dan Lichtenfeld.

Participated · Equity · May 2019

LeQuest provides simulation-based educational solutions for high-risk medical technology used in operating rooms, intensive care units and radiology departments. The company trains and certifies healthcare professionals in the use of medical devices and has serviced both hospitals and manufacturers. It works with device makers including Philips, Siemens, Medtronic and GE and reports active users in more than 15 countries across Europe, North and South America. Founded in 2011 and led by CEO Hicham Shatou, LeQuest is based in Rotterdam, The Netherlands. The company intends to use new funds to intensify collaboration with device manufacturers and to expand its services to hospitals geographically. The business model centers on simulation-based education and certification tied to medical technology adoption and use.

Participated · Seed · Dec 2016

Noona Healthcare offers a cloud-based oncology platform that captures patient-reported outcomes to help cancer centers identify severe symptoms earlier. The company is led by CEO Jani Ahonala and is based in Helsinki, Finland. Its main partners include Stanford Medicine and Helsinki University Cancer Center. Noona completed a €1.5m seed funding round to support its growth. The company intends to use the funds to continue scaling the business globally. The platform targets cancer centers seeking intelligence to improve symptom detection and patient monitoring.